KALA BIO’s (KALA) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of KALA BIO (NASDAQ:KALA) in a report released on Friday,Benzinga reports. The firm currently has a $15.00 price objective on the stock.

Separately, Oppenheimer reissued an “outperform” rating and set a $15.00 target price on shares of KALA BIO in a report on Monday, August 19th.

KALA BIO Price Performance

KALA BIO stock opened at $6.60 on Friday. KALA BIO has a 12 month low of $4.21 and a 12 month high of $10.97. The company has a current ratio of 2.15, a quick ratio of 3.07 and a debt-to-equity ratio of 3.18. The business’s 50 day simple moving average is $6.03 and its 200 day simple moving average is $6.28. The company has a market cap of $30.43 million, a price-to-earnings ratio of -0.53 and a beta of -2.13.

KALA BIO (NASDAQ:KALA) last issued its earnings results on Tuesday, November 12th. The company reported ($1.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.43) by $0.50. Sell-side analysts forecast that KALA BIO will post -11.01 EPS for the current year.

Institutional Investors Weigh In On KALA BIO

A hedge fund recently bought a new stake in KALA BIO stock. SR One Capital Management LP bought a new stake in shares of KALA BIO, Inc. (NASDAQ:KALA) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO accounts for about 1.0% of SR One Capital Management LP’s portfolio, making the stock its 9th biggest holding. SR One Capital Management LP owned about 15.76% of KALA BIO as of its most recent filing with the Securities and Exchange Commission. 24.61% of the stock is owned by institutional investors and hedge funds.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.